{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000343","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.228983+00:00","generated_at":"2026-06-19T02:59:06.314559+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Edgewise reports Q4 2022 net loss $19.4M; cash $352M; advancing EDG-5506 and EDG-7500 trials","bullets":["Cash, cash equivalents and marketable securities of $352M as of Dec 31, 2022.","Q4 2022 net loss $19.4M ($0.31 per share); R&D expenses $16.6M, G&A $5.5M.","EDG-7500 for HCM entered IND-enabling studies; Phase 1 start expected 2H2023.","LYNX Phase 2 DMD trial interim data expected Q4 2023; ARCH BMD 12-month data Q2 2023.","CANYON BMD trial to be amended with potentially registration-enabling cohort in 2H2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000343","json":"https://secwatch.observer/filing/0001157523-23-000343.json","markdown":"https://secwatch.observer/filing/0001157523-23-000343.md","text":"https://secwatch.observer/filing/0001157523-23-000343.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752323000343/0001157523-23-000343-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752323000343/a53339740.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:59:06.314559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}